Talaris Therapeutics, Inc. (TALS)

7.37 +0.27 (+3.80%) At close: 04:00PM EDT

Talaris Therapeutics, Inc.

570 South Preston Street
Louisville, KY 40202
United States
502-398-9250
https://talaristx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 112

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA	Pres, CEO, Sec. & Director	544.76k	N/A	1968
Dr. Suzanne T. Ildstad M.D.	Founder, Chief Scientific Officer & Director	486.07k	N/A	1953
Ms. Nancy Krieger M.D.	Chief Medical Officer	482.76k	N/A	1967
Ms. Mary Kay Fenton	Chief Financial Officer	N/A	N/A	1964
Mr. Michael Zdanowski	Chief Technology Officer	N/A	N/A	1967
Ms. Suzanne Tollerud	VP of Corp. Devel. & Treasurer	N/A	N/A	N/A
Mr. Roderick D. Purdy	VP of HR	N/A	N/A	1957
Mr. Eric Gornstein	Head of New Product Planning	N/A	N/A	N/A
Ms. Farah Natoli	Head of Portfolio & Program Management	N/A	N/A	N/A
Mr. Colby Suire Ph.D.	Head of R&D	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Corporate governance

Talaris Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.